Autolus Ltd. said it submitted a confidential draft registration statement to the U.S. Securities and Exchange Commission for a potential IPO in the U.S.
The U.K.-based biopharmaceutical company is yet to determine the timing and the terms of the IPO.
The developer of chimeric antigen receptor T cell, or CAR-T, therapies for cancer was spun out of University College London in 2014.
